and efficacy of concizumab ents with inhibitors Explorer 7 trial design Novo Nordisk ® 1) Maintained OnD treatment R 1:2 2) Concizumab prophylaxis 3) Concizumab prophylaxis 4) Concizumab prophylaxis Extension with concizumab prophylaxis Main part 32 weeks 1 Extension part 136 weeks ng number of bleeding ors of the main phase Key inclusion criteria • Males ≥12 years with haemophilia and inhibitors, treated with bypassing agents within last 24 weeks • For on-demand, minimum six bleeding episodes within last 24 weeks
Download PDF file